Blog
RSS FeedPosted by Michael Wonder on 13 Feb 2025
NICE joins international collaboration on HTA methods research
12 February 2025 - We’ve partnered with the US based ICER and the Canadian Drug Agency (CDA-AMC) to establish the Health ...
Posted by Michael Wonder on 01 Feb 2025
Refined interpretation of the Mutual Recognition Agreement between Canada and Switzerland
31 January 2025 - Swissmedic and Health Canada agreed to expand their approach regarding the implementation of the current mutual ...
Posted by Michael Wonder on 23 Jan 2025
EU-HTA: maintaining the achievements of AMNOG
20 January 2025 - IQWiG welcomes the fact that the adjustments to the AMNOG procedure planned for the integration with European ...
Posted by Michael Wonder on 19 Jan 2025
New EU rules for health technology assessments become effective
10 January 2025 - Enhanced EU collaboration to allow faster and wider access to innovative health technologies. ...
Posted by Michael Wonder on 17 Jan 2025
International collaboration provides new guidance on the use of surrogate outcomes in cost effectiveness analysis
17 January 2025 - Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits ...
Posted by Michael Wonder on 16 Dec 2024
Findings from the EUnetHTA 21 project for EU-HTA from 2025
12 December 2024 - The results from EUnetHTA 21 provide insights for future cooperation in EU-HTA: participants from IQWiG and ...
Posted by Michael Wonder on 30 May 2024
European Commission adopts rules for joint clinical assessments
29 May 2024 - The European Commission has adopted joint clinical assessment rules detailing how national health care systems should ...
Posted by Michael Wonder on 23 May 2024
COTA announces extended collaboration with FDA to advance the use of real world data in cancer research
22 May 2024 - Today, COTA announced an extension of its research collaboration with the US FDA Oncology Center of Excellence. ...
Posted by Michael Wonder on 20 May 2024
Global cooperation and early access—clinical outcomes matter
13 May 2024 - In modern cancer drug development, surrogate measures are commonly used as clinical trial endpoints instead of more ...
Posted by Michael Wonder on 16 May 2024
Delegation from Taiwan visits IQWiG
15 May 2024 - At the end of April 2024, Mao-Ting Sheen visited the Institute for Quality and Efficiency in Healthcare ...
Posted by Michael Wonder on 18 Apr 2024
FINOSE now covers all Nordic countries
18 April 2024 - Icelandic Landspitali joins the Nordic collaboration FINOSE, where HTA authorities from the Nordic countries carry out ...
Posted by Michael Wonder on 18 Mar 2024
Co-design of an enhanced consumer engagement process
18 March 2024 - A consumer-led Co-design Working Group has developed proposed recommendations for enhancing consumer engagement processes to enable ...
Posted by Michael Wonder on 04 Mar 2024
Together for high standards in the assessment of health technologies in Europe from 2025
1 March 2024 - A few months before the EU HTA regulation came into force, a delegation from the French HTA ...
Posted by Michael Wonder on 07 Feb 2024
FDA and EMA launch parallel scientific advice pilot program for complex generics
7 February 2024 - CDER’s Office of Generic Drugs and the EMA launched a voluntary pilot program to facilitate concurrent discussions ...
Posted by Michael Wonder on 06 Feb 2024
Updates on NICE and SMC collaboration on MTA for cystic fibrosis
1 February 2024 - On 19 December 2023, we advised that NICE would be liaising with key stakeholders to determine ...